Drug Trial Radar · NCT02004860
Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis
Last checked: Nov 20, 2026Latest source record: May 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jan 2014
Primary completion
Oct 2017
Study completion Oct 2017
Sponsor
- Lead sponsor
- University Hospital, RouenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp. It would be important to have a maintenance treatment for severe forms of seborrheic dermatitis witch is both effective and relatively well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack treatment and reduce the use of topical steroids.
Conditions
- Severe Seborrheic Dermatitis
Interventions
Protopic (R)Drug
Protopic® 0.1% ointment - 2 applications per week for 6 months
Mycoster (R)Drug
Mycoster 1% - 2 applications per week for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- duration of the maintenance of complete or almost complete clinical remissionTime frame: 18 months after inclusion (Visit (V) 4 last visit)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rouen University Hospital
Rouen, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.